Innoviva (INVA) Amortization - Deferred Charges (2017 - 2026)
Innoviva posted quarterly Amortization - Deferred Charges of $3.5 million for Q1 2026, little changed year-on-year from $3.5 million in Q1 2025, and little changed on a QoQ basis from $3.5 million in Q3 2025.
Innoviva (INVA) has 10 years of Amortization - Deferred Charges data on file, last reported at $3.5 million in Q1 2026.
- For the quarter ending Q1 2026, Amortization - Deferred Charges changed 0.0% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (changed 0.0% YoY), and the FY2025 full-year result was $13.8 million, changed 0.17% from the prior year.
- Amortization - Deferred Charges for Q1 2026 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
- Across five years, Amortization - Deferred Charges topped out at $3.5 million in Q1 2022 and bottomed at $3.5 million in Q1 2022.
- The 5-year median for Amortization - Deferred Charges is $3.5 million (2022), against an average of $3.5 million.
- Peak annual rise in Amortization - Deferred Charges reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
- A 5-year view of Amortization - Deferred Charges shows it stood at $3.5 million in 2022, then changed by 0.0% to $3.5 million in 2023, then changed by 0.0% to $3.5 million in 2024, then changed by 0.0% to $3.5 million in 2025, then changed by 0.0% to $3.5 million in 2026.
- The last three Amortization - Deferred Charges figures came in at $3.5 million (Q1 2026), $3.5 million (Q3 2025), and $3.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 3.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.46 Mn |
| Mar 31, 2026 | 3.46 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.46 Mn |
| Mar 31, 2025 | 3.46 Mn |
| Mar 31, 2025 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.46 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Mar 31, 2024 | 3.46 Mn |
| Sep 30, 2023 | 3.46 Mn |
| Sep 30, 2023 | 3.46 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Mar 31, 2023 | 3.46 Mn |
| Mar 31, 2023 | 3.46 Mn |
| Sep 30, 2022 | 3.46 Mn |
| Sep 30, 2022 | 3.46 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Jun 30, 2022 | 3.46 Mn |
| Mar 31, 2022 | 3.46 Mn |
| Mar 31, 2022 | 3.46 Mn |
| Sep 30, 2021 | 3.46 Mn |
| Sep 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 3.46 Mn |
| Jun 30, 2021 | 3.46 Mn |
| Mar 31, 2021 | 3.46 Mn |
| Mar 31, 2021 | 3.46 Mn |
| Dec 31, 2020 | 3.46 Mn |
| Dec 31, 2020 | 3.46 Mn |
| Sep 30, 2020 | 3.46 Mn |
| Sep 30, 2020 | 3.46 Mn |
| Jun 30, 2020 | 3.46 Mn |
| Jun 30, 2020 | 3.46 Mn |
| Mar 31, 2020 | 3.46 Mn |
| Mar 31, 2020 | 3.46 Mn |
| Dec 31, 2019 | 3.43 Mn |
| Dec 31, 2019 | 3.43 Mn |
| Sep 30, 2019 | 3.46 Mn |
| Sep 30, 2019 | 3.46 Mn |
| Jun 30, 2019 | 3.46 Mn |
| Jun 30, 2019 | 3.46 Mn |
| Mar 31, 2019 | 3.46 Mn |
| Mar 31, 2019 | 3.46 Mn |
| Dec 31, 2018 | 3.43 Mn |
| Dec 31, 2018 | 3.43 Mn |
| Sep 30, 2018 | 3.46 Mn |
| Sep 30, 2018 | 3.46 Mn |
| Jun 30, 2018 | 3.46 Mn |
| Jun 30, 2018 | 3.46 Mn |
| Mar 31, 2018 | 3.46 Mn |
| Mar 31, 2018 | 3.46 Mn |
| Dec 31, 2017 | 3.43 Mn |
| Dec 31, 2017 | 3.43 Mn |
| Sep 30, 2017 | 3.46 Mn |
| Sep 30, 2017 | 3.46 Mn |